Caninized il31rΑ antibodies with an extended half life
Caninized antibodies with specific Fc region modifications address the limitations of current therapies by enhancing half-life and efficacy in treating atopic dermatitis in dogs, achieving prolonged therapeutic effects.
WO2026125321A1PCT designated stage Publication Date: 2026-06-18INTERVET INT BV +1
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- INTERVET INT BV
- Filing Date
- 2025-12-09
- Publication Date
- 2026-06-18
Smart Images
Figure IMGF000021_0001 
Figure IMGF000022_0001 
Figure IMGF000045_0001
Abstract
The present invention generally relates to canine IgG antibodies or antigen binding proteins thereof, comprising a canine IgG modified fragment crystallizable region (Fc region) that has an enhanced half-life due to one or more specific amino acid substitutions in the Fc region. Specifically, the present invention relates to canine antibodies that bind canine interleukin-31 receptor alpha (IL31RA), comprising a canine fragment crystallizable region (cFc) that comprises an amino acid residue other than glutamine (Q) at position 311. Pharmaceutical compositions that comprise these antibodies are also provided.
Need to check novelty before this filing date? Find Prior Art